Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced non-small-cell lung cancer: the PUMA trial

[1]  M. Alber,et al.  Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  J. Debus,et al.  Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations , 2022, Frontiers in Oncology.

[3]  Haihua Yang,et al.  Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial? , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  J. Debus,et al.  Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung , 2020, Frontiers in Oncology.

[5]  W. Ryder,et al.  Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study , 2020, International journal of radiation oncology, biology, physics.

[6]  D. Lynch,et al.  Expanding Applications of Pulmonary MRI in the Clinical Evaluation of Lung Disorders: Fleischner Society Position Paper. , 2020, Radiology.

[7]  C. Belka,et al.  Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer , 2020, Radiation oncology.

[8]  K. Kaira,et al.  Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy , 2020, AntiCancer Research.

[9]  L. Kepka,et al.  Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: A phase I/II study. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Sonja Adebahr,et al.  Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. , 2020, The Lancet. Oncology.

[11]  S. Senan,et al.  Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors. , 2020, International journal of radiation oncology, biology, physics.

[12]  Suresh Senan,et al.  Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Suresh Senan,et al.  Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. , 2019, International journal of radiation oncology, biology, physics.

[14]  Sebastian Klüter,et al.  Technical design and concept of a 0.35 T MR-Linac , 2019, Clinical and translational radiation oncology.

[15]  K. Frey,et al.  Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  M. Barton,et al.  MRI-Linear Accelerator Radiotherapy Systems. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  Parag J. Parikh,et al.  Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial , 2018, Advances in radiation oncology.

[18]  Marcel van Herk,et al.  Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis. , 2018, International journal of radiation oncology, biology, physics.

[19]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[20]  J P Cuijpers,et al.  Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Randall K Ten Haken,et al.  Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[22]  Sara Ramella,et al.  Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  J. Bradley,et al.  Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Markus Alber,et al.  Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  P. Harari,et al.  Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Jinzhong Yang,et al.  Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. Sonke,et al.  Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  J. Aerts,et al.  Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  R. Salgia,et al.  Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). , 2015, International journal of radiation oncology, biology, physics.

[30]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[31]  Jan-Jakob Sonke,et al.  Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  Benjamin Movsas,et al.  Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  Philippe Giraud,et al.  Respiratory Gating Techniques for Optimization of Lung Cancer Radiotherapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  M. Partridge,et al.  Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. , 2011, International journal of radiation oncology, biology, physics.

[35]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[36]  M. Ridder,et al.  Toxicity report of a phase 1/2 dose‐escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy , 2009, Cancer.

[37]  Hisao Asamura,et al.  The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[39]  Wolfgang A Tomé,et al.  Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? , 2006, International journal of radiation oncology, biology, physics.

[40]  Suresh Senan,et al.  Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. , 2005, International journal of radiation oncology, biology, physics.

[41]  J. Galvin,et al.  Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Benjamin Movsas,et al.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[43]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[44]  R Mackie,et al.  A new approach to dose escalation in non-small-cell lung cancer. , 2001, International journal of radiation oncology, biology, physics.